Median survival for MM has historically been approximately years with of patients experiencing complete remission upon treatment with conventional therapy, such as melphalan and prednisone or vincristine, doxorubicin, dexamethasone, prior to the advent of novel therapies. Bortezomib, a reversible inhibitor of the 26S proteasome, has anti-tumor activity conferred by multiple mechanisms. Clinical studies suggest that bortezomib is effective for the treatment of MM and offers improved remission and better survival. At present there are bortezomib based combination chemotherapy with 2 or 3 drugs,(+)-JQ1 but there is no clear strategy for choosing a regimen for different patients since few clinical trials are supported. Thus, we retrospectively analyzed the efficacy and adverse effects experienced by MM patients who received combination therapy based on bortezomib as the first-line therapy from three hematological centers in China and we report our findings here. MM is one of the most frequently observed hematologic cancers With an incidence in China of 1–2 per 100,000. Patients who can achieve CR are reported to be significantly improved with respect to PFS and OS whether in the patients received high-dose chemotherapy with ASCT or without ASCT, or relapse/ refractory patients. Recently years, many prospective randomized clinical trials have pushed forth advances in the treatment of MM with targeted drugs,ABT-199 such as bortezomib-, thalidomide-, and lenalidomie-based regimens, effects of which have been reported to be significantly better than traditional therapies. However, few clinical trials have compared regimens to develop a strategy to direct initial MM treatment, especially for the OS and patient quality of life. At this time, regimens in China are mainly bortezomib-based therapies, including doublet regimens, and triplet regimes such as PCD, PAD and PTD. Bortezomib, as a component of these protocols is given. Dexamethasone is given at 160 mg for every course and sometimes as high as 480 mg every course.